A single hormone result may not describe the long-term risk faced by a person with a benign adrenal tumor. In a large international study, cortisol classifications changed over time for a substantial share of patients, while persistently elevated cortisol tracked with worsening blood-pressure control. The pattern challenges the idea that one early test settles the matter for years.
The finding concerns a defined adrenal-tumor population and repeated testing, not routine cortisol screening for every adult.
Researchers followed 2,525 patients for years
The University of Birmingham report describes 2,525 patients treated at 25 specialist centers in 14 countries. Follow-up averaged nearly seven years. Each patient had repeated overnight dexamethasone suppression tests, the standard method used in the study to assess autonomous cortisol production.
The participants had benign adrenal tumors discovered during medical care. Such growths can sometimes produce cortisol outside normal regulatory control, creating mild autonomous cortisol secretion. The study tracked whether test results remained normal, remained elevated or moved between those categories.
Cortisol status changed in 22 percent
Researchers found that 22 percent of patients changed classification during follow-up, with most changes occurring within the first three years after diagnosis. That movement is the reason a single measurement can miss a later risk pattern.
Hormone results can vary for several reasons, and a changed category does not automatically mean that a tumor became dangerous. The value of repetition is in distinguishing a temporary or borderline result from a pattern that stays abnormal over time.
Persistent elevation carried the heavier burden
Patients with persistently elevated cortisol had the greatest overall cardiometabolic burden in the study. Their rate of worsening high blood pressure was 34 percent higher than among patients whose cortisol remained normal. Over ten years, they averaged two fewer years of well-controlled, hypertension-free time.
The comparison links a sustained hormone pattern with blood-pressure progression; it does not prove that cortisol was the only cause. Weight, diabetes, cholesterol, smoking and other health factors can also shape cardiovascular risk and require management alongside the adrenal finding.
The overnight test remains useful but incomplete
The dexamethasone test checks whether a small steroid dose suppresses cortisol as expected. Failure to suppress can indicate autonomous secretion from an adrenal tumor. The new evidence does not make the test unreliable; it shows that a result at one moment may not remain the same.
Current guidelines reserve repeat testing for selected clinical circumstances. The study authors called for prospective work to determine whether routine repetition improves decisions beyond monitoring blood pressure, glucose, weight and other established risk markers.
Follow-up may focus on the higher-risk pattern
Persistently abnormal results may help identify patients who need closer cardiovascular follow-up or evaluation of active treatment. Surgery can be appropriate in selected cases, but the study does not turn every benign adrenal tumor into an operation.
A clinician can combine hormone trends with tumor imaging, symptoms, age and other medical conditions. Repeated testing is most useful when it changes that overall assessment rather than producing an isolated number with no plan attached.
The study’s contribution is a timeline: cortisol behavior in adrenal-tumor patients can evolve, and persistent excess carries more cardiovascular concern than one abnormal result alone. That makes long-term pattern recognition more informative than assuming the first test is permanent.
Adrenal tumors are often discovered incidentally during imaging performed for another reason. That means many patients have no obvious hormone symptoms at diagnosis. Blood pressure, glucose and cholesterol trends can provide practical signs that a previously quiet finding deserves renewed endocrine attention.
Persistent mild cortisol excess differs from the dramatic presentation of severe Cushing syndrome. The subtler state can still influence metabolic and cardiovascular health over years, which is why a long follow-up study can reveal differences that a short snapshot misses.
Repeated testing also carries costs and the possibility of borderline results that create anxiety without changing care. Future trials must show not only that categories move, but that a defined retesting schedule leads to better treatment decisions and outcomes.
Blood-pressure changes accumulate quietly, which makes longitudinal records valuable. A patient may feel no different while medication requirements rise or control worsens. Linking hormone patterns with those clinical changes gives the laboratory result a concrete cardiovascular outcome.
The study’s 14-country network improves geographic breadth, but specialist centers may see more complex cases than ordinary clinics. Community-based follow-up would help determine how often cortisol categories change among patients managed outside endocrine referral centers.
Imaging follow-up remains separate from hormone follow-up. Tumor size and appearance help clinicians assess structural concern, while cortisol testing addresses function. A stable-looking mass can still produce hormone, and a changing laboratory value does not necessarily mean that the mass has grown. Longitudinal care depends on both kinds of information.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- A Colorado wildfire forced level-three ‘leave now’ orders across Ouray County
- A skeleton beneath Petra’s Treasury was found clutching a chalice that resembles the Holy Grail
- 8 SUVs mechanics are quietly steering buyers away from in 2026
- Researchers pulled 8,080 pounds of invasive python from one Florida county
